STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today
that it will host a conference call to discuss its fiscal 2019
fourth quarter and full year financial results at 10:00 a.m.
Eastern Time on Tuesday, May 14, 2019. The conference call can be
heard live over the Internet at www.steris-ir.com or via phone by
dialing 1-833-535-2199 in the United States or 1-412-902-6776
internationally, then asking to join the conference call for STERIS
plc.
A press release detailing fourth quarter and full
year 2019 financial results will be issued after the U.S. market
closes on May 13, 2019.
For those unable to listen to the conference call
live, a replay will be available beginning at 12:00 p.m. Eastern
Time on May 14, 2019, either over the Internet at www.steris-ir.com
or via phone. To access the replay of the call, please use the
access code 10129994 and dial 1-877-344-7529 in the United States
or 1-412-317-0088 internationally.
About STERIS
STERIS’s mission is to help our Customers create a
healthier and safer world by providing innovative healthcare and
life science product and service solutions around the globe. For
more information, visit www.steris.com.
Investor Contact:Julie Winter,
Senior Director, Investor Relations and Corporate
CommunicationsJulie_Winter@steris.com+1.440.392.7245
Media Contact:Stephen Norton,
Senior Director, Corporate
CommunicationsStephen_Norton@steris.com+1.440.392.7482
Forward-Looking Statements
This release and the referenced conference call may
contain statements concerning certain trends, expectations,
forecasts, estimates, or other forward-looking information
affecting or relating to STERIS or its industry, products or
activities that are intended to qualify for the protections
afforded “forward-looking statements” under the Private Securities
Litigation Reform Act of 1995 and other laws and regulations.
Forward-looking statements speak only as to the date the statement
is made and may be identified by the use of forward-looking terms
such as “may,” “will,” “expects,” “believes,” “anticipates,”
“plans,” “estimates,” “projects,” “targets,” “forecasts,”
“outlook,” “impact,” “potential,” “confidence,” “improve,”
“optimistic,” “deliver,” “orders,” “backlog,” “comfortable,”
“trend”, and “seeks,” or the negative of such terms or other
variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation,
disruption of production or supplies, changes in market conditions,
political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory
agencies, and changes in laws, government regulations, labeling or
product approvals or the application or interpretation thereof.
Other risk factors are described in STERIS’s securities filings,
including Item 1A of STERIS’s Annual Report on Form 10-K for
the year ended March 31, 2018. Many of these important factors
are outside of STERIS’s control. No assurances can be provided as
to any result or the timing of any outcome regarding matters
described in STERIS’s securities filings or otherwise with respect
to any regulatory action, administrative proceedings, government
investigations, litigation, warning letters, cost reductions,
business strategies, earnings or revenue trends or future financial
results. References to products are summaries only and should not
be considered the specific terms of the product clearance or
literature. Unless legally required, STERIS does not undertake to
update or revise any forward-looking statements even if events make
clear that any projected results, express or implied, will not be
realized. Other potential risks and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, (a) the
parties’ ability to meet expectations regarding the accounting and
tax treatments of the redomiciliation transaction, (b) operating
costs, Customer loss and business disruption (including, without
limitation, difficulties in maintaining relationships with
employees, Customers, clients or suppliers) being greater than
expected following the redomiciliation transaction, (c) STERIS’s
ability to meet expectations regarding the accounting and tax
treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility
that anticipated benefits resulting from the TCJA will be less than
estimated, (d) changes in tax laws or interpretations that
could increase our consolidated tax liabilities, including changes
in tax laws that would result in STERIS being treated as a domestic
corporation for United States federal tax purposes, (e) the
potential for increased pressure on pricing or costs that leads to
erosion of profit margins, (f) the possibility that market
demand will not develop for new technologies, products or
applications or services, or business initiatives will take longer,
cost more or produce lower benefits than anticipated, (g) the
possibility that application of or compliance with laws, court
rulings, certifications, regulations, regulatory actions, including
without limitation those relating to FDA warning notices or
letters, government investigations, the outcome of any pending FDA
requests, inspections or submissions, or other requirements or
standards may delay, limit or prevent new product introductions,
affect the production and marketing of existing products or
services or otherwise affect STERIS’s performance, results,
prospects or value, (h) the potential of international unrest,
economic downturn or effects of currencies, tax assessments,
tariffs and/or other trade barriers, adjustments or anticipated
rates, raw material costs or availability, benefit or retirement
plan costs, or other regulatory compliance costs, (i) the
possibility of reduced demand, or reductions in the rate of growth
in demand, for STERIS’s products and services, (j) the
possibility of delays in receipt of orders, order cancellations, or
delays in the manufacture or shipment of ordered products or in the
provision of services, (k) the possibility that anticipated
growth, cost savings, new product acceptance, performance or
approvals, or other results may not be achieved, or that
transition, labor, competition, timing, execution, regulatory,
governmental, or other issues or risks associated with STERIS’s
businesses, industry or initiatives including, without limitation,
those matters described in STERIS’s 10-K for the year ended
March 31, 2018 and other securities filings, may adversely
impact STERIS’s performance, results, prospects or value,
(l) the impact on STERIS and its operations, or tax
liabilities, of Brexit or the exit of other member countries from
the EU, and the Company’s ability to respond to such impacts,
(m) the impact on STERIS and its operations of any
legislation, regulations or orders, including but not limited to
any new trade or tax legislation, regulations or orders, that may
be implemented by the U.S. administration or Congress, or of any
responses thereto, (n) the possibility that anticipated
financial results or benefits of recent acquisitions, or of
STERIS’s restructuring efforts, or of recent divestitures, or of
the targeted restructuring plan will not be realized or will be
other than anticipated, and (o) the effects of contractions in
credit availability, as well as the ability of STERIS’s Customers
and suppliers to adequately access the credit markets when
needed.
STERIS (NYSE:STE)
Historical Stock Chart
From Aug 2024 to Sep 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Sep 2023 to Sep 2024